Company intelligence / Profile preview

SYNTHRON

Nijmegen, Gelderland, Nederlandprotex-international.com ↗

Ownership: Private
Employees: ~1600
Development stage: Commercial

Overview

Synthon is a global leader in the development and manufacturing of complex generic pharmaceuticals with over three decades of experience. The company has launched more than 70 molecules commercially across approximately 100 countries. Its biopharmaceutical efforts include preclinical biologic candidates such as an anti-CD20 antibody for oncology indications[1][2][6].

Therapeutic areas: Men's HealthOncologyHematologyPsychiatryCardiovascular
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Partners for commercialization globally; products are often marketed by partners rather than under the Synthon brandGoldman Sachs Private Equity invested in December,2024

Beyond the preview

Go deeper on SYNTHRON.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYNTHRON.

Explore the full profile